SNY - Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play

2024-06-18 10:05:23 ET

Summary

• Apogee Therapeutics stock has declined by 34% since a previous recommendation to buy, while the S&P 500 is up 7.7%.
• Apogee Therapeutics raised $420 million at $62/share, expanding their financial runway while advancing APG777 into Phase 2 trials.
• APG777, targeting atopic dermatitis and asthma, shows promise with less frequent dosing, aiming to compete with Sanofi's Dupixent.
• I recommend buying APGE stock, focusing on a barbell strategy to manage risks and capitalize on potential high returns.

Apogee Therapeutics: Analyzing the Recent Decline Amidst Innovations

Apogee Therapeutics, Inc. ( APGE ) stock has taken a breather since my last check in March. APG777 , their Phase 1 SQ monoclonal antibody targeting IL-13, was the primary focus at the time. The biologic's Phase 1 data showed that it could be dosed as infrequently as every three to six months. This would be a significant improvement over Sanofi's ( SNY ) multibillion-dollar Dupixent monthly dosing....

For further details see: